When a Genome Becomes a Strategic Asset

What the politicization of genomic data means for the sequencing instrumentation market 

Key Takeaways 

• 100 US persons vs. 10,000: The DOJ’s Data Security Program restricts bulk transfers of human genomic data at just 100 US persons — two orders of magnitude below the threshold for health or financial data, the clearest signal yet of how governments now value genomic data as a strategic asset. 

• China’s Illumina ban previewed the mechanism: When China named Illumina an “unreliable entity” in 2025 and blocked hardware imports while letting consumables flow, regional vendor leadership changed hands within a single fiscal year. 

• The installed base cushions near-term revenue: Because consumables and service — not new instrument sales — make up the bulk of sequencing revenue, hardware export restrictions cap future growth without immediately denting current-quarter results. 

• Procurement eligibility is now a product spec: Since the BIOSECURE Act restricts federally funded labs from purchasing from designated suppliers, buyers increasingly select platforms on jurisdictional grounds alongside read length, accuracy, and cost per gigabase. 

• Regional growth is diverging for non-technical reasons: Research funding policy, procurement rules, and reimbursement decisions — not scientific demand — are driving materially different growth paths across major geographies through 2030. 

In March 2025, the genetic profiles of roughly 15 million people were listed as assets in a Chapter 11 filing. The bankruptcy of 23andMe forced a question that two decades of consumer genomics had managed not to answer: when a company holding your DNA fails, what exactly is on the auction block? 

A bankruptcy court eventually approved a sale to a nonprofit led by the company’s founder, with privacy commitments attached and a court-appointed consumer privacy ombudsman brought in to referee. Legislators noticed. Within months, bipartisan bills, including one titled the Don’t Sell My DNA Act, were circulating in the Senate. 

For most readers, that was a privacy story. For anyone modeling the sequencing market, it was something more consequential. It was the moment genomic data stopped being treated as scientific output and started being treated as a strategic asset, with all the export controls, procurement restrictions, and sovereignty claims that such a designation tends to attract. 

The instruments that generate that data have inherited the same status. And that changes how the market should be analyzed. Here, we share several observations from SDi’s newly published Market Landscape: Sequencing report which demonstrate how the sequencing market is being shaped by forces outside of technological advances and end user needs. 

The 100-person threshold 

The clearest signal of how governments now value genomic data is buried in a US Department of Justice rule that took effect in April 2025. Under the Data Security Program implementing Executive Order 14117, bulk transfers of sensitive US personal data to a set of countries of concern are restricted once they cross defined volume thresholds: 

• Precise geolocation data: 1,000 devices 

• Personal health and financial data: 10,000 individuals 

• Human genomic data: 100 US persons 

That is the lowest threshold of any data category in the rule, by two orders of magnitude. It is not a privacy judgment so much as a valuation. A hundred genomes are treated as strategically equivalent to ten thousand health records. Once a government prices an asset that way, the infrastructure that produces it becomes infrastructure worth controlling. 

The sequencer as a trade instrument 

That logic became explicit in early 2025, when China named Illumina, the market’s dominant sequencing vendor, an “unreliable entity” and blocked imports of its instruments in retaliation over lobbying around US biosecurity legislation. The design of the restriction is worth examining in detail: 

• Hardware: blocked 

• Consumables for the existing installed base: continued to flow 

The ban was eased late in the year following a US-China trade framework, but the listing itself remains, and prospective buyers still require government approval to purchase. 

The commercial consequence arrived within a single fiscal year. Leadership of that regional market changed hands, not because a competitor shipped a better instrument, but because policy made the incumbent’s instrument difficult to buy. Our analysis of regional vendor positioning through 2025 shows that shift clearly, and it is the cleanest natural experiment the sequencing market has produced on how quickly share moves when procurement is constrained regardless of technical performance. 

The US has been constructing a mirror image response. The BIOSECURE Act was enacted in December 2025 as part of the FY2026 National Defense Authorization Act, restricting federal agencies and recipients of federal funding from procuring biotechnology equipment or services from designated “biotechnology companies of concern.” One nuance that gets lost in the coverage: the enacted text dropped the named-company list that appeared in earlier drafts, which included China-based sequencing supplier MGI Tech. Designations now run through an interagency process, with the initial list due in December 2026, the US Office of Management and Budget implementing guidance up to 180 days after that, and Federal Acquisition Regulation amendments a year later. 

For market participants and investors, the timeline matters as much as the substance. The affected vendors are broadly predictable from existing Department of Defense watchlists, and the practical bite arrives on a multi-year schedule with waiver authority and transition provisions attached. That is a gradual shift to model, not an event. Already, MGI Tech is reacting, with the planned divestment of its California-based subsidiary Complete Genomics, which it has agreed to sell to Swiss life sciences group Swiss Rockets AG. 

Europe’s version is quieter but structurally similar. The European Health Data Space entered into force in March 2025 and routes secondary research access to health data through national access bodies and secure processing environments. Genomic data, notably, is carved out of that regime until 2031, leaving a six-year interim in which cross-border genomic research in the EU has no harmonized legal pathway, at exactly the moment several large national population sequencing programs are scaling up. 

Why this is a market-structure question 

Several features of the sequencing market turn all of this from a legal footnote into a forecasting variable. 

• The installed base is the asset. The overwhelming majority of sequencing revenue is recurring: consumables and service against instruments already in the field, with initial system sales a comparatively small slice of the total. Our 2025 breakdown of demand by product type makes the asymmetry stark. This is why an export restriction that blocks hardware while permitting reagents is such an elegant instrument of pressure: it leaves current revenue nearly intact while quietly capping the future. The damage compounds over the replacement cycle rather than appearing in the next quarter. 

• Procurement eligibility is becoming a product specification. When a federally funded lab cannot purchase from a designated supplier, eligibility sits on the evaluation sheet alongside read length, accuracy, and cost per gigabase. Several credible new platforms have entered the market since 2022 with genuinely differentiated chemistries; a subset of buyers will now select among them on jurisdictional grounds rather than technical ones. Technology roadmaps and market share have partially decoupled. 

• Regional trajectories are diverging for non-technical reasons. The regional forecasts in our latest sequencing analysis show materially different growth paths across the major geographies through 2030, driven by research funding policy, procurement rules, and reimbursement decisions rather than by differences in scientific demand. That divergence is widening, not converging, which makes geographic revenue mix a sharper differentiator between vendors than it has been at any point in the history of the market. 

Questions worth asking now 

For participants in the sequencing market, the geopolitical layer begs additional diligence questions that would not have been issues just five years ago. 

• What is the jurisdictional concentration of revenue, and how much of it sits in markets where procurement is politically contingent? Reported regional segments rarely map neatly onto regulatory exposure. 

• How durable is the installed base under restriction? An instrument that cannot be replaced still consumes reagents. The relevant question is what happens at the end of the replacement cycle, not next quarter. 

• What is the designation risk, and on what timeline does it bite? Designation lists, entity listings, and data-transfer thresholds all operate on published schedules. The market tends to price them as binary events when they are, in practice, phased. 

The underlying market is still growing 

None of this changes the fundamental picture. Sequencing remains a multi-billion-dollar market with a positive growth outlook across every major region through 2030, sustained by a recurring revenue base that has proven resilient through a genuinely difficult funding environment. What has changed is that the competitive landscape can no longer be read from a technology roadmap alone. 

SDi’s Sequencing Market Landscape covers that landscape in full: five-year forecasts segmented by product type, region, end market, sector, and application; 2025 vendor share; detailed profiles of the established leaders and the recent entrants challenging them; and a detailed treatment of the regulatory and litigation environment shaping who can sell what, and where. 

Go Deeper: Related SDi Research 

• SDi’s Market Landscape: Sequencing provides five-year forecasts segmented by product type, region, end market, sector, and application, plus 2025 vendor share and detailed profiles of established leaders and emerging challengers. 

---

Frequently Asked Questions